Associated tags: Medicine, OGM, Patient, Spectrum, Biology, Genome, Software, SAN, Genomics, Doctor of Philosophy, Research
Locations: SWITZERLAND, MASSACHUSETTS, HAMILTON, NEVADA, LONG, UNITED STATES, UKRAINE, RUSSIA, GEORGIA, SPAIN, LOS ANGELES, RENO, NEW YORK CITY, ISRAEL, SAN DIEGO, CA, US, BEIJING, NEW YORK, CHINA, FLORIDA
Nanopore,
Nanopore sequencing,
OGM,
University Medical Center,
Doctor of Philosophy,
Leukemia,
BMA,
Genomics,
Bone marrow,
SVS,
SAN,
University Medical Center Groningen OGM has been shown to regularly detect SVs missed by other methods, as a result of the higher resolution and sensitivity of OGM.
Key Points:
- OGM has been shown to regularly detect SVs missed by other methods, as a result of the higher resolution and sensitivity of OGM.
- Some of OGM’s novel findings, however, are difficult for other methods to validate, because of their resolution limitations.
- The study results highlight OGM’s ability to provide researchers with a more comprehensive understanding of leukemia subtypes and the potential of targeted Cas9-directed Nanopore sequencing to validate new findings efficiently and at high resolution, compared to other genome analysis methods, including short read or other long read sequencing methods.
- “We were pleased to see researchers conclude that the findings detected by OGM in leukemia samples were robust and superior to classical cytogenetic methods.
Cytogenetics,
Pregnancy,
NMPA,
OGM,
Partnership,
OEM,
Doctor of Philosophy,
Research,
Artificial intelligence,
Karyotype,
Fertilisation,
Genomics,
Bone marrow,
SVS,
SAN,
Medical device Bionano, a global leader in the transformation of the cytogenetic workflow with optical genome mapping (OGM), has entered into a strategic partnership with Hangzhou Diagens Biotechnology Co., Ltd. (Diagens), the pioneering leader in artificial intelligence (AI) chromosome karyotype analysis technology.
Key Points:
- Bionano, a global leader in the transformation of the cytogenetic workflow with optical genome mapping (OGM), has entered into a strategic partnership with Hangzhou Diagens Biotechnology Co., Ltd. (Diagens), the pioneering leader in artificial intelligence (AI) chromosome karyotype analysis technology.
- Diagens has received Class I registration and approval for Bionano’s OGM reagents from China's NMPA and will register the Saphyr™ instrument with NMPA for clinical use in reproductive health.
- “As a pioneer in AI chromosome karyotype analysis, we are very happy to establish a partnership with Bionano and to jointly explore the reproductive health market.
- Diagens offers cutting-edge AI technology to help our customers to achieve a better overall success rate of in vitro fertilization.
B-ALL,
OGM,
RNA,
WGS,
Genetic variation,
Doctor of Philosophy,
Research,
Leukemia,
Bone marrow,
Biomarker,
Genomics,
Whole genome sequencing,
Cancer,
SVS,
SAN,
Vaccine The study also used whole genome sequencing (WGS) for variant detection and evaluated the two approaches side-by-side and the potential benefit of integrating WGS and OGM to obtain a comprehensive analysis of genetic variation.
Key Points:
- The study also used whole genome sequencing (WGS) for variant detection and evaluated the two approaches side-by-side and the potential benefit of integrating WGS and OGM to obtain a comprehensive analysis of genetic variation.
- The study concluded that OGM together with WGS can potentially identify new therapeutic targets and improve personalized medicine in pediatric leukemia and other cancers by providing a more complete view of genome variation, including structural variation.
- The study findings showed that, of the 3,075 total SVs detected in the B-ALL samples, 1,255 were uniquely detected by OGM.
- The study also found that WGS detected 66 gene fusions, and that OGM was able to detect an additional 56 fusions that were missed by WGS.
The closing of the offering is expected to occur on or about April 8, 2024, subject to the satisfaction of customary closing conditions.
Key Points:
- The closing of the offering is expected to occur on or about April 8, 2024, subject to the satisfaction of customary closing conditions.
- The gross proceeds to the Company from the offering are expected to be approximately $10 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
- The securities described above are being offered and sold by the Company in a registered direct offering pursuant to a “shelf” registration statement on Form S-3 (File No.
- The offering of such securities in the registered direct offering is being made only by means of a base prospectus and prospectus supplement that forms a part of the effective registration statement.
Sarcoma,
Diagnosis,
KT,
Oncogene,
SAN,
Neoplasm,
Research,
Cancer,
Doctor of Philosophy,
CDKN2A,
Workflow,
Karyotype,
FISH,
Genomics,
Chromothripsis,
SVS,
Prognosis,
Aberration,
OGM,
Medical imaging Sarcomas represent over 100 histological subtypes and are highly heterogenous in their genetic landscape and prognosis.
Key Points:
- Sarcomas represent over 100 histological subtypes and are highly heterogenous in their genetic landscape and prognosis.
- The detection of SVs and CNVs remains challenging and typically requires multiple traditional cytogenetic techniques.
- In this study, researchers demonstrated OGM’s ability to detect aberrations as small as 500 bp, which is approximately 10,000-fold higher resolution than that of KT.
- As shown in this study, OGM can provide better characterization of the genomic complexity of sarcoma samples when compared to traditional cytogenetic techniques, due to the workflow’s high resolution and comprehensive, genome-wide analysis.
SAN,
NGS,
Research,
Classification,
Cancer,
Software,
AACR,
Genomics,
VAF,
Bone marrow,
OGM,
VIA,
Medicine,
Medical imaging AACR’s annual meeting brings together industry, medical, and academic professionals to discuss advances in cancer science and medicine.
Key Points:
- AACR’s annual meeting brings together industry, medical, and academic professionals to discuss advances in cancer science and medicine.
- The AACR conference will be held April 5-10, 2024, in San Diego, California.
- Bionano will introduce its new Stratys™ system, which offers higher throughput and improved sample flexibility, to the cancer research community at the conference.
- Nine scientific poster presentations will illustrate OGM’s utility for cancer research in areas including solid tumors, hematological malignancies, as well as applications in cell and gene therapy and cell manufacturing and bioprocessing quality control.
Ovarian cancer,
DNA repair,
Breast,
SAN,
Neoplasm,
DNA,
HBOC,
Doctor of Philosophy,
Medicine,
Genomics,
Chromothripsis,
SVS,
Breast cancer,
HRD,
BRCA2,
OGM,
BRCA1,
Drug resistance,
Medical imaging HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.
Key Points:
- HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.
- The study authors selected OGM for this analysis due to its ability to detect multiple classes of SVs with genome-wide coverage, high resolution and accuracy.
- Eight novel gene fusions were identified by OGM, including three that had not previously been detected by other methods of analysis.
- “We are pleased to see the publication of this study, which highlights OGM as a promising tool for detecting novel variants in HBOC-related breast cancer that have oncogenic potential.
SAN,
Medical college,
Medical College of Wisconsin,
Vancouver General Hospital,
DSM-IV codes,
American College,
ACMG,
OGM,
LGG,
Medical genetics,
DRS,
Research,
Cancer,
Medical device Dr. Tara Spence from Vancouver General Hospital will present insights into her laboratory’s adoption of Stratys and its potential impact on hematological malignancy analysis
Key Points:
- Dr. Tara Spence from Vancouver General Hospital will present insights into her laboratory’s adoption of Stratys and its potential impact on hematological malignancy analysis
A scientific platform presentation will feature Drs.
- ACMG’s Annual Meeting brings together industry, medical, and academic professionals to discuss advances in clinical genetics research.
- The ACMG conference will be held March 12-16, 2024, in Toronto, Canada.
- All scientific posters will be presented in Exhibit Halls DE.
SAN,
Doctor of Philosophy,
Research,
FDA,
Data collection,
Growth,
Overalls,
Sale,
Genomics,
NGS,
DSM-IV codes,
Standard of care,
IRB,
Bone marrow,
GAAP,
Medicare,
First Step,
Genome,
Data analysis,
Symposium,
OGM,
Met,
Publication,
Comment,
SOC,
DNA,
Cancer,
Workflow,
Video game Total revenue for the fourth quarter of 2023 was $10.7 million, an increase of 30% compared to the fourth quarter of 2022.
Key Points:
- Total revenue for the fourth quarter of 2023 was $10.7 million, an increase of 30% compared to the fourth quarter of 2022.
- GAAP gross margin for the fourth quarter of 2023 was 23%, which was slightly higher than the 22% GAAP gross margin reported for the fourth quarter of 2022.
- Fourth quarter 2023 GAAP operating expense was $27.4 million, compared to $39.3 million in the fourth quarter of 2022.
- Fourth quarter 2023 non-GAAP operating expense was $27.3 million, compared to $30.6 million in the fourth quarter of 2022.
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at TD Cowen’s 44th Annual Health Care Conference on March 6, 2024.
Key Points:
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at TD Cowen’s 44th Annual Health Care Conference on March 6, 2024.
